Pediatric Neurology News

Children with a neurologic comorbidity experienced an almost twofold greater risk for postoperative pneumonia, according to results from a retrospective study published in Pediatrics.

The FDA today approved Nexviazyme, an IV infusion, for the treatment of late-onset Pompe disease among patients aged 1 year and older, according to a press release.

Adrenocorticotropic hormone and oral steroids demonstrated superiority compared with non-standard therapy for the initial treatment of infantile spams in a prospective, multicenter observational cohort study published in Neurology.

Several factors, including pediatric ICU admission and multispecialty care, increased length of stay and costs at pediatric neurology hospitals, according to results of a retrospective review published in Journal of Child Neurology.

High school students’ bed and wake-up times have been delayed amid the COVID-19 pandemic, and they have become more active during the evening, according to study results published in Journal of Clinical Sleep Medicine.

The presence of pain in children with cerebral palsy can make motor skill activities even more difficult, according to a research letter published in JAMA Network Open.

A school-based health and mindfulness program improved objective measurements of sleep over a 2-year period in children from communities of low socioeconomic status, according to findings published in Journal of Clinical Sleep Medicine.

Better screening protocols and new, potentially more effective treatments have created “an opportune time” for the implementation of newborn screening for Duchenne muscular dystrophy, according to a viewpoint published in JAMA Neurology.

Extremely preterm infants with prolonged exposure to opioids and benzodiazepines experienced an increased risk for worse neurodevelopmental outcomes at 2 years’ corrected age, according to results from a cohort study.

Viltepso, an injection treatment for Duchenne muscular dystrophy in patients with a confirmed mutation, demonstrated a statistically significant benefit for motor function in open-label extension results from a phase 2 study.